Summary: PCSK9 is a protein that breaks down hepatocyte LDL receptors, raising blood LDL cholesterol. PCSK9 inhibitors (evolocumab·alirocumab) are antibodies that block the PCSK9 protein itself. Inclisiran (Leqvio) is an siRNA that degrades PCSK9 mRNA so the protein never gets made. Both deliver 50~60% LDL reduction. The difference is dosing — antibodies require self-injection every 2 weeks, siRNA needs a clinic injection just twice a year.

What Is PCSK9

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein secreted by liver cells. Its role: bind to LDL receptors on the hepatocyte surface, enter the cell together, and direct LDL receptors to the lysosome for degradation. Result:

LDL receptors ↓ → blood LDL absorption ↓ → blood LDL ↑
Higher PCSK9 activity = harder to lower LDL

This mechanism was discovered in 2003 when a French research team identified PCSK9 mutations in families with familial hypercholesterolemia. Gain-of-function mutations cause very high LDL + early cardiovascular disease. Loss-of-function mutations correlate with low LDL + cardiovascular protection. The hypothesis “block PCSK9 → lower LDL” naturally moved into clinical development.

Two Blocking Strategies

1. Monoclonal Antibody (block PCSK9 protein)

Evolocumab (Repatha): 2015 FDA approval
Alirocumab (Praluent): 2015 FDA approval
Mechanism: directly binds PCSK9 protein → prevents binding to LDL receptor
Dosing: subcutaneous self-injection every 2 or 4 weeks (thigh·abdomen)
Effect: 50~60% LDL reduction (added on top of statin)
Clinical: FOURIER (evolocumab 27,564 patients), ODYSSEY OUTCOMES (alirocumab 18,924 patients) — 15~17% reduction in cardiovascular events

2. siRNA (degrade PCSK9 mRNA)

Inclisiran (Leqvio): 2021 EMA, 2021 FDA approval
Mechanism: GalNAc-conjugated siRNA targets hepatocytes → RISC complex recognizes + cleaves PCSK9 mRNA → no PCSK9 protein produced
Dosing: month 0, month 3, then every 6 months in clinic
Effect: 50~55% LDL reduction
Clinical: ORION-9·10·11 (3,074 patients) — LDL reduction + safety. ORION-4 (15,000 patients) cardiovascular outcomes expected 2027

Action Circuit

[Antibody strategy]
Blood PCSK9 ─antibody bind→ blocked → LDL receptors preserved → LDL absorption↑ → blood LDL↓

[siRNA strategy]
Hepatocyte PCSK9 mRNA ─siRNA cleaves→ no PCSK9 protein → LDL receptors preserved → LDL absorption↑ → blood LDL↓

Who Uses It (Indications)

FDA·EMA common:

Familial hypercholesterolemia (heterozygous·homozygous)
Clinical atherosclerotic cardiovascular disease (ASCVD) + LDL above target on max statin
Statin intolerance (myalgia·hepatic enzyme elevation)

2026 ACC/AHA new guideline shift:

Postmenopausal women: universal LDL <100 mg/dL target
Statin first → ezetimibe add-on → PCSK9 inhibitor or inclisiran
Guideline officially adds PCSK9 class to LDL ladder for all patients

Effect Comparison

Strategy	LDL reduction	Dosing	US price
Statin (atorvastatin 80mg)	40~50%	Daily oral	Very low
Add ezetimibe	+15~20%	Daily oral	Low
PCSK9 antibody	50~60%	SC every 2 weeks	Very high
Inclisiran siRNA	50~55%	IM every 6 months	Very high

PCSK9 antibody and inclisiran show essentially equivalent LDL-lowering effect. Difference lies in dosing convenience and patient adherence. siRNA only requires 2 clinic visits per year.

Side Effects·Cautions

Common:

Injection site reaction (mild pain·erythema)
Nasopharyngitis
Antibody: allergic reactions very rare
siRNA: immunogenicity·long-term safety data accumulating

Female-specific considerations:

Pregnancy·lactation safety data lacking → contraception recommended for women of childbearing potential
Effect in postmenopausal women equivalent to men (FOURIER subgroup analysis)
2026 ACC/AHA guideline establishes universal LDL <100 target for postmenopausal women → expected increase in usage

Cost·Accessibility

US:

Antibody (Repatha·Praluent): ~~$5,000~~6,000/year (post-insurance)
Inclisiran (Leqvio): ~$6,500/year (high unit cost but only 6-month dosing)

Korea:

Repatha·Praluent: 5% out-of-pocket under specialty disease cost reimbursement for familial hypercholesterolemia + cardiovascular high-risk
Inclisiran: 2024 MFDS approval. 2026 insurance reimbursement negotiation in progress

Future — Longer, Stronger

In development:

Lerodalcibep: monthly PCSK9 antibody pen self-injection
VERVE-101 / VERVE-102: base editing single injection that permanently silences the PCSK9 gene (Verve Therapeutics phase 1) — potential lifetime LDL lowering

PCSK9 blockade may expand from a routine drug to a lifetime single procedure. However, long-term safety of gene editing requires 10~20 years of accumulated data.

FAQ

Q. Should it be combined with statin? A. Generally added when statin at maximum dose still leaves LDL above target. If statin-intolerant, monotherapy is acceptable.

Q. What if LDL drops too low after PCSK9 inhibition? A. Patients with LDL below 25 mg/dL show no short or medium-term safety issues. No neurological abnormalities reported. Long-term data still accumulating.

Q. Is 6-month dosing really enough? A. Inclisiran’s siRNA stably binds the RISC complex inside hepatocytes and continues to degrade PCSK9 mRNA for 6+ months. ORION-11 confirmed sustained LDL reduction at the 6-month mark.

Q. Can diet·exercise lower PCSK9? A. Diet·exercise can lower LDL but PCSK9 itself isn’t meaningfully modulated outside of pharmacological intervention or gene editing.

Q. Oral PCSK9 inhibitor? A. Merck’s MK-0616 (enlicitide), an oral macrocyclic peptide, is in phase 3. Oral availability would substantially improve access.

Conclusion

PCSK9 inhibition is the second revolution in LDL lowering after the statin era. Antibody·siRNA tracks are advancing in parallel, and the 2026 ACC/AHA guideline now recommends universal use including postmenopausal women. The future of 6-month injections·single gene editing is also in sight. Lifetime LDL management is shifting from daily pills to periodic procedures.

PCSK9·Inclisiran — siRNA-Based LDL Cholesterol Lowering Mechanism